Evaluation of a 15‐weekCHOPprotocol for the treatment of canine multicentric lymphoma

Abstract

AbstractDose intenseCHOPprotocols have been shown to improve outcome for people with non‐Hodgkin's lymphoma, but evaluation of dose intenseCHOPprotocols for canine lymphoma is currently limited. The hypothesis of this retrospective study was that a 15‐week dose intenseCHOPprotocol would have shorter treatment duration with similar efficacy to other doxorubicin‐based multidrug protocols. Thirty‐one client owned dogs with multicentric lymphoma were treated with a 15‐weekCHOPchemotherapy protocol with an overall response rate of 100% and a median progression‐free interval (PFI) of 140 days [95% confidence interval (CI) 91–335 days]. Dogs that had two or more treatment delays had significantly prolongedPFIand overall survival in multivariate analysis. Dose intensity did not correlate with patient outcome. Dogs experiencing multiple treatment delays secondary to adverse events may receive their individual maximally tolerated dose while dogs with no adverse events may be underdosed. Future studies should focus on individual patient dose optimization.